Argenx has been granted a patent for combination therapies targeting chronic airway diseases, particularly asthma. The therapies include antagonists of IL-5 and IL-4/IL-13, as well as bispecific antibodies designed to bind to IL-4Ra and IL-5, enhancing treatment options for patients. GlobalData’s report on Argenx gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Argenx, Personalized cancer vaccines was a key innovation area identified from patents. Argenx's grant share as of June 2024 was 32%. Grant share is based on the ratio of number of grants to total number of patents.
Combination therapies for treating asthma using bispecific antibodies
The granted patent US12030949B2 describes a multispecific antibody designed to target human interleukin-5 (IL-5) and interleukin-4 receptor (IL-4R). The antibody comprises specific heavy chain (VH) and light chain (VL) variable regions that include defined complementarity-determining regions (CDRs) for both IL-5 and IL-4R. The claims detail the amino acid sequences for these regions, referencing specific sequence IDs (SEQ ID NOs) that provide the structural basis for the antibody's functionality. The patent outlines various configurations of the antibody, including those with at least 90% sequence identity to the specified SEQ IDs, and includes claims for both bispecific antibodies and those exhibiting differential binding activity at varying pH levels.
Additionally, the patent specifies that the multispecific antibody may demonstrate lower antigen-binding activity at acidic pH compared to neutral pH, with a defined ratio of binding activities. The claims further elaborate on the specific amino acid sequences that can be utilized for the heavy and light chains of the antibody targeting IL-5 and IL-4R, providing a comprehensive framework for the development of this therapeutic agent. The detailed nature of the claims emphasizes the potential for targeted therapeutic applications in conditions associated with IL-5 and IL-4R, such as asthma and other allergic diseases.
To know more about GlobalData’s detailed insights on Argenx, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
